Indeed, the selective high expression of DNGR-1 in cDC1s has been previously used as a target for delivering cancer antigens to cDC1.17 Moreover, although we have found no role for DNGR-1 in tumor antigen cross-presentation in the steady state, there may be potential cancer immunotherapy contexts where the role of DNGR-1 in tumor dead cell antigen cross-presentation may prevail, favoring antitumor immunity. This evidence concerns the gene CLEC9A and cancer.